Stockreport

Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

Lexicon Pharmaceuticals, Inc.  (LXRX) 
Last lexicon pharmaceuticals, inc. earnings: 4/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: lexpharma.com/investors
PDF Top-line Data Now Anticipated in Q1 2025  LX9211 has previously received Fast Track designation from the U.S. Food and Drug Administration (FDA) for DPNP  THE WOODLA [Read more]